What is Bloom Science?
Founded in 2017 and headquartered in San Diego, Bloom Science operates at the intersection of advanced biology and pharmaceutical innovation. The company is dedicated to the discovery and development of microbiome therapeutics, a field that leverages the human gut ecosystem to treat a variety of chronic and age-related diseases. By focusing on the modulation of the microbiome, Bloom Science aims to create novel drug candidates that offer safer and more effective alternatives to traditional pharmacological interventions. Their market position is defined by a commitment to rigorous scientific validation and the pursuit of transformative health outcomes for patients globally.
How much funding has Bloom Science raised?
Bloom Science has raised a total of $12.1M across 2 funding rounds:
Debt
$95K
Series A
$12M
Debt (2021): $95K with participation from PPP
Series A (2021): $12M led by Bayer, Joyance Partners, Apollo Health Ventures, and ALS Investment Fund
Key Investors in Bloom Science
Bayer
Bayer is a global enterprise in the life science fields of healthcare and nutrition, supporting efforts to overcome major challenges presented by a growing and aging global population.
Joyance Partners
Joyance invests in companies that leverage science and technology to enhance quality of life, focusing on health and consumer sectors from pre-seed to Series A stages.
Apollo Health Ventures
Apollo Health Ventures is a transatlantic early-stage venture capital firm focused on investing in transformative healthcare companies that address age-related diseases and aging.
What's next for Bloom Science?
With the recent infusion of capital, Bloom Science is poised to scale its therapeutic pipeline and advance its lead candidates through critical clinical milestones. The strategic focus will likely center on expanding laboratory capabilities, strengthening intellectual property portfolios, and fostering collaborative partnerships with global life science leaders. As the company transitions into a more mature phase of development, the emphasis will shift toward optimizing manufacturing processes and preparing for regulatory engagement. This major enterprise-level funding provides the necessary runway to navigate the complexities of drug development, ensuring that the firm remains at the forefront of the microbiome revolution while delivering long-term value to stakeholders and patients alike.
See full Bloom Science company page
